Compare TBPH & OLPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TBPH | OLPX |
|---|---|---|
| Founded | 2013 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Package Goods/Cosmetics |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.0B |
| IPO Year | 2013 | 2021 |
| Metric | TBPH | OLPX |
|---|---|---|
| Price | $13.86 | $1.27 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $18.50 | $1.69 |
| AVG Volume (30 Days) | 782.6K | ★ 1.7M |
| Earning Date | 05-07-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.88 | N/A |
| Revenue | $15,386,000.00 | ★ $422,960,000.00 |
| Revenue This Year | $70.90 | $4.28 |
| Revenue Next Year | N/A | $3.68 |
| P/E Ratio | $15.75 | ★ N/A |
| Revenue Growth | N/A | ★ 0.07 |
| 52 Week Low | $7.90 | $0.99 |
| 52 Week High | $21.03 | $1.84 |
| Indicator | TBPH | OLPX |
|---|---|---|
| Relative Strength Index (RSI) | 27.74 | 39.70 |
| Support Level | $13.41 | $1.24 |
| Resistance Level | $14.76 | $1.55 |
| Average True Range (ATR) | 0.58 | 0.11 |
| MACD | -0.08 | -0.03 |
| Stochastic Oscillator | 11.29 | 14.75 |
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
Olaplex Holdings Inc is a science-enabled, technology-driven beauty company. It offers science-backed solutions that improve hair health. It identifies the majority of consumers' relevant haircare concerns in collaboration with the community of professional hairstylists and consumers and strives to address them through its proprietary technology and innovation capabilities. It offers products through an omnichannel platform that serves professional, specialty retail, and DTC channels. The company derives its revenue through the sale of its hair care products. The company generates the majority of revenue from Professional sales channels followed by Specialty Retail and then DTC. Geographically the company generates the majority of its revenue from the International market.